Catalyst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPRX)

$4.15 -0.02 (-0.48 %)
(As of 12/14/2017 09:54 AM ET)
Previous Close$4.17
Today's Range$4.14 - $4.29
52-Week Range$1.01 - $4.51
Volume876,700 shs
Average Volume986,765 shs
Market Capitalization$427.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Debt-to-Equity RatioN/A
Current Ratio12.60%
Quick Ratio12.60%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book8.83

Profitability

Trailing EPS($0.21)
Net Income$-18,070,000.00
Net MarginsN/A
Return on Equity-48.86%
Return on Assets-45.62%

Miscellaneous

Employees18
Outstanding Shares102,470,000

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) posted its quarterly earnings data on Wednesday, May, 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). View Catalyst Pharmaceuticals' Earnings History.

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?

4 brokers have issued 12-month price targets for Catalyst Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they expect Catalyst Pharmaceuticals' share price to reach $6.25 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:

  • Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer (Age 68)
  • Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer (Age 44)
  • Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer (Age 53)
  • David D. Muth, Executive Vice President, Chief Commercial Officer (Age 60)
  • M. Douglas Winship, Vice President - Regulatory Operations (Age 66)
  • David J. Caponera, Vice President - Patient Advocacy & Reimbursement (Age 58)
  • Bernardino Mosquera M.D., Vice President - Clinical Operations (Age 47)
  • Charles B. O'Keeffe, Lead Independent Director (Age 75)
  • Gary Ingenito M.D., Chief Medical Officer (Age 52)
  • Richard J. Daly, Director (Age 64)

Who owns Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (1.79%), GSA Capital Partners LLP (0.56%), Crestline Management LP (0.26%), OxFORD Asset Management LLP (0.16%) and SG Americas Securities LLC (0.07%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Who sold Catalyst Pharmaceuticals stock? Who is selling Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Crestline Management LP, SG Americas Securities LLC and OxFORD Asset Management LLP. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $4.15.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $427.32 million. The biopharmaceutical company earns $-18,070,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 18 workers across the globe.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]


MarketBeat Community Rating for Catalyst Pharmaceuticals (CPRX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catalyst Pharmaceuticals (NASDAQ:CPRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.25$5.50$5.50$4.75
Price Target Upside: 45.35% upside83.95% upside109.92% upside186.14% upside

Catalyst Pharmaceuticals (NASDAQ:CPRX) Consensus Price Target History

Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017Piper Jaffray CompaniesSet Price TargetPositive -> Buy$8.00LowView Rating Details
11/29/2017SunTrust BanksReiterated RatingBuy$6.00HighView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy$6.00N/AView Rating Details
11/1/2017Roth CapitalSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earnings History and Estimates Chart

Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ CPRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.06)($0.05)ViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20172($0.07)($0.05)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 34.83%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Patrick J McenanyInsiderBuy20,000$2.58$51,600.00View SEC Filing  
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catalyst Pharmaceuticals (NASDAQ CPRX) News Headlines

Source:
DateHeadline
Catalyst Pharmaceuticals (CPRX) Rating Lowered to Buy at BidaskClubCatalyst Pharmaceuticals (CPRX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - December 9 at 7:16 PM
Reviewing Vertex Pharmaceuticals (VRTX) & Catalyst Pharmaceuticals (CPRX)Reviewing Vertex Pharmaceuticals (VRTX) & Catalyst Pharmaceuticals (CPRX)
www.americanbankingnews.com - December 9 at 1:48 AM
 Analysts Expect Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 EPS Analysts Expect Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 EPS
www.americanbankingnews.com - December 7 at 5:28 PM
Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Buy" from AnalystsCatalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 6:26 AM
Catalyst Pharmaceuticals (CPRX) "Buy" Rating Reaffirmed at SunTrust BanksCatalyst Pharmaceuticals' (CPRX) "Buy" Rating Reaffirmed at SunTrust Banks
www.americanbankingnews.com - November 29 at 4:44 PM
Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common StockCatalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock
finance.yahoo.com - November 28 at 5:16 PM
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in ... - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 8:34 AM
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 28 at 8:34 AM
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial ofCatalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of
www.nasdaq.com - November 27 at 6:11 PM
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockCatalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 27 at 6:11 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research to "Sell"Catalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 25 at 12:14 PM
Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy ... - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy ... - GlobeNewswire (press release)
globenewswire.com - November 23 at 4:15 AM
In The Spotlight: Catalyst Pharmaceuticals - Nasdaq.com - NasdaqIn The Spotlight: Catalyst Pharmaceuticals - Nasdaq.com - Nasdaq
www.nasdaq.com - November 20 at 3:04 AM
In The Spotlight: Catalyst PharmaceuticalsIn The Spotlight: Catalyst Pharmaceuticals
www.rttnews.com - November 19 at 5:00 PM
FY2020 EPS Estimates for Catalyst Pharmaceuticals, Inc. Lowered by Analyst (CPRX)FY2020 EPS Estimates for Catalyst Pharmaceuticals, Inc. Lowered by Analyst (CPRX)
www.americanbankingnews.com - November 13 at 10:30 AM
Catalyst Pharmaceuticals, Inc. (CPRX) Receives "Buy" Rating from HC WainwrightCatalyst Pharmaceuticals, Inc. (CPRX) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - November 10 at 10:24 AM
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 - NasdaqCatalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 - Nasdaq
www.nasdaq.com - November 10 at 5:56 AM
Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update - NasdaqCatalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update - Nasdaq
www.nasdaq.com - November 9 at 3:07 AM
Have Investors Already Priced In Catalyst Pharmaceuticals Inc’s (CPRX) Growth?Have Investors Already Priced In Catalyst Pharmaceuticals Inc’s (CPRX) Growth?
finance.yahoo.com - November 8 at 10:06 PM
Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateCatalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 10:06 PM
Catalyst reports 3Q lossCatalyst reports 3Q loss
finance.yahoo.com - November 8 at 10:06 PM
What's in Store for Catalyst (CPRX) This Earnings Season?What's in Store for Catalyst (CPRX) This Earnings Season?
finance.yahoo.com - November 6 at 6:46 PM
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017
finance.yahoo.com - November 1 at 6:22 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by SunTrust Banks, Inc. AnalystsCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by SunTrust Banks, Inc. Analysts
www.americanbankingnews.com - November 1 at 3:22 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by Roth Capital AnalystsCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - November 1 at 3:22 PM
Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic SyndromeCatalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome
finance.yahoo.com - October 31 at 6:42 PM
Catalyst Pharmaceuticals, Inc. (CPRX) to Release Earnings on TuesdayCatalyst Pharmaceuticals, Inc. (CPRX) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
Analyzing Catalyst Pharmaceuticals (CPRX) & Chimerix (CMRX)Analyzing Catalyst Pharmaceuticals (CPRX) & Chimerix (CMRX)
www.americanbankingnews.com - October 21 at 8:14 AM
Catalyst Pharmaceutical (CPRX) Presents At 2017 BIO Investor Forum - SlideshowCatalyst Pharmaceutical (CPRX) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 19 at 6:01 PM
Catalyst Pharmaceuticals (CPRX) & Its Peers Critical AnalysisCatalyst Pharmaceuticals (CPRX) & Its Peers Critical Analysis
www.americanbankingnews.com - October 19 at 6:26 AM
Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor ForumCatalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum
finance.yahoo.com - October 16 at 6:14 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment ResearchCatalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 12 at 12:20 AM
Catalyst Pharmaceuticals (CPRX) versus Endocyte (ECYT) Head to Head ReviewCatalyst Pharmaceuticals (CPRX) versus Endocyte (ECYT) Head to Head Review
www.americanbankingnews.com - September 30 at 2:24 PM
Short Interest in Catalyst Pharmaceuticals, Inc. (CPRX) Declines By 35.4%Short Interest in Catalyst Pharmaceuticals, Inc. (CPRX) Declines By 35.4%
www.americanbankingnews.com - September 29 at 1:28 AM
-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter
www.americanbankingnews.com - September 22 at 4:28 PM
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates - NasdaqCatalyst (CPRX) Focused on Two Lead Pipeline Candidates - Nasdaq
www.nasdaq.com - September 19 at 10:31 PM
Catalyst (CPRX) Focused on Two Lead Pipeline CandidatesCatalyst (CPRX) Focused on Two Lead Pipeline Candidates
finance.yahoo.com - September 18 at 5:28 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Insider Patrick J. Mcenany Purchases 20,000 SharesCatalyst Pharmaceuticals, Inc. (CPRX) Insider Patrick J. Mcenany Purchases 20,000 Shares
www.americanbankingnews.com - September 5 at 4:46 PM
Catalyst Pharmaceuticals (CPRX) Buy Rating Reiterated at SunTrust Banks, Inc.Catalyst Pharmaceuticals' (CPRX) Buy Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - September 5 at 9:42 AM
 Analysts Expect Catalyst Pharmaceuticals, Inc. (CPRX) to Announce -$0.06 Earnings Per Share Analysts Expect Catalyst Pharmaceuticals, Inc. (CPRX) to Announce -$0.06 Earnings Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
Catalyst Pharmaceuticals Provides Update on the Status of its ... - NasdaqCatalyst Pharmaceuticals Provides Update on the Status of its ... - Nasdaq
www.nasdaq.com - August 31 at 10:22 PM
Catyalyst Pharma (CPRX) Provides Update on the Status of its Firdapse; Sees NDA Submitted in First Quarter of 2018Catyalyst Pharma (CPRX) Provides Update on the Status of its Firdapse; Sees NDA Submitted in First Quarter of 2018
www.streetinsider.com - August 31 at 5:21 PM
Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities - GlobeNewswire (press release)Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities - GlobeNewswire (press release)
globenewswire.com - August 30 at 6:31 PM
Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development ActivitiesCatalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities
finance.yahoo.com - August 30 at 6:31 PM
Catalyst (CPRX) Focused on Development of Pipeline CandidatesCatalyst (CPRX) Focused on Development of Pipeline Candidates
www.nasdaq.com - August 15 at 6:12 PM
Catalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of ($0.05) Per Share, SunTrust Banks Forecasts (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of ($0.05) Per Share, SunTrust Banks Forecasts (NASDAQ:CPRX)
www.americanbankingnews.com - August 14 at 6:42 AM
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Issues Quarterly  Earnings ResultsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
Catalyst Pharmaceutical Partners (CPRX) CEO Patrick McEnany on Q1 2017 Results - Earnings Call Transcript - Seeking AlphaCatalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 6:46 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target at Roth CapitalCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target at Roth Capital
www.americanbankingnews.com - August 10 at 3:22 PM
Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update - NasdaqCatalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update - Nasdaq
www.nasdaq.com - August 9 at 5:38 PM

SEC Filings

Catalyst Pharmaceuticals (NASDAQ:CPRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catalyst Pharmaceuticals (NASDAQ:CPRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catalyst Pharmaceuticals (NASDAQ CPRX) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.